Literature DB >> 8733439

Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees.

C Belcher1, F Fawthrop, R Bunning, M Doherty.   

Abstract

OBJECTIVES: To establish baseline concentrations of plasminogen activators and their inhibitors in normal knee synovial fluids, and to compare them with well characterised osteoarthritis (OA) and rheumatoid arthritis (RA) knee fluids.
METHODS: A total of 26 normal subjects, 71 patients with OA, and 17 patients with RA underwent knee aspiration. Patients with OA were subclassified according to presence of nodal generalised OA (NGOA) and synovial fluid calcium pyrophosphate crystals. Clinical assessment of inflammation (graded 0-6) was undertaken in OA and RA patients. Plasminogen activator (PA), plasminogen activator inhibitor (PAI), and urokinase-type PA receptor (uPAR) antigen concentrations were determined by enzyme linked immunosorbent assay. The species of PAs present were determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis.
RESULTS: Concentrations of all antigens (uPA, tissue-type PA (tPA), uPAR, and PAI-1), were significantly greater in RA than OA; those in OA were significantly greater than normal. The concentrations showed no direct association with clinically assessed inflammation of the knee. In normal fluids, no associations with age were observed. Antigen concentrations (uPA, tPA, and uPAR) in NGOA differed from those in other subclasses of OA, but the species of PA present did not appear to vary between disease groups. The predominant PA appeared to have identity with uPA.
CONCLUSION: Because of the greater concentrations of these antigens in OA compared with normal fluids, OA cannot be used as a surrogate normal control in studies of the PA/PAI system. Alteration of the PA/PAI system was confirmed in RA and OA knee fluids, with greater changes evident in RA. The finding of different concentrations of PA antigens in NGOA compared with other OA fluids further supports a different pathogenic mechanism in this subset.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733439      PMCID: PMC1010143          DOI: 10.1136/ard.55.4.230

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  34 in total

1.  Action of plasmin on cartilage.

Authors:  C H LACK; H J ROGERS
Journal:  Nature       Date:  1958-10-04       Impact factor: 49.962

2.  Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells.

Authors:  B S Knudsen; P C Harpel; R L Nachman
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

Review 3.  Plasminogen activators and their inhibitors: regulators of extracellular proteolysis and cell function.

Authors:  D A Hart; A Rehemtulla
Journal:  Comp Biochem Physiol B       Date:  1988

Review 4.  Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.

Authors:  F Blasi
Journal:  Bioessays       Date:  1993-02       Impact factor: 4.345

5.  Plasminogen activator in synovial fluid from patients with rheumatoid arthritis.

Authors:  H Kikuchi; S Tanaka; O Matsuo
Journal:  J Rheumatol       Date:  1987-06       Impact factor: 4.666

6.  Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts.

Authors:  J A Hamilton; D Cheung; E L Filonzi; D S Piccoli; J Wojta; M Gallichio; K McGrath; K Last
Journal:  Arthritis Rheum       Date:  1992-12

7.  Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases.

Authors:  J A Kummer; J J Abbink; J P de Boer; D Roem; E J Nieuwenhuys; A M Kamp; T J Swaak; C E Hack
Journal:  Arthritis Rheum       Date:  1992-08

8.  The role of plasminogen in interleukin-1 mediated cartilage degradation.

Authors:  S Collier; P Ghosh
Journal:  J Rheumatol       Date:  1988-07       Impact factor: 4.666

9.  A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.

Authors:  J D Vassalli; D Baccino; D Belin
Journal:  J Cell Biol       Date:  1985-01       Impact factor: 10.539

10.  Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor.

Authors:  R L Nachman; K A Hajjar; R L Silverstein; C A Dinarello
Journal:  J Exp Med       Date:  1986-06-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Urokinase in rheumatoid arthritis: causal or coincidental?

Authors:  N Busso; A So
Journal:  Ann Rheum Dis       Date:  1997-12       Impact factor: 19.103

Review 2.  Intra-articular corticosteroid injections in osteoarthritis: do they work and if so, how?

Authors:  P Creamer
Journal:  Ann Rheum Dis       Date:  1997-11       Impact factor: 19.103

3.  Ultrasound guided intra-articular ketorolac versus corticosteroid injection in osteoarthritis of the hip: a retrospective comparative study.

Authors:  Ki Deok Park; Tai Kon Kim; Byung Woo Bae; JaeKi Ahn; Woo Yong Lee; Yongbum Park
Journal:  Skeletal Radiol       Date:  2015-06-03       Impact factor: 2.199

4.  Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees.

Authors:  C Belcher; R Yaqub; F Fawthrop; M Bayliss; M Doherty
Journal:  Ann Rheum Dis       Date:  1997-05       Impact factor: 19.103

5.  Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.

Authors:  N Busso; V Péclat; A So; A P Sappino
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

6.  Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.

Authors:  O Slot; N Brünner; H Locht; P Oxholm; R W Stephens
Journal:  Ann Rheum Dis       Date:  1999-08       Impact factor: 19.103

7.  Fibrinolysis is down-regulated in mouse collagen-induced arthritis, but its normalization does not alleviate the course of disease.

Authors:  Jakub Kwieciński; Elisabet Josefsson; Tao Jin
Journal:  Inflamm Res       Date:  2011-07-24       Impact factor: 4.575

8.  The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis.

Authors:  Jinan Li; Annelii Ny; Göran Leonardsson; Kutty Selva Nandakumar; Rikard Holmdahl; Tor Ny
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

9.  The urokinase receptor promotes cancer metastasis independently of urokinase-type plasminogen activator in mice.

Authors:  Minji Jo; Shinako Takimoto; Valerie Montel; Steven L Gonias
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

10.  Exacerbation of antigen-induced arthritis in urokinase-deficient mice.

Authors:  N Busso; V Péclat; K Van Ness; E Kolodziesczyk; J Degen; T Bugge; A So
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.